Claus Neurohr

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

Jürgen Behr, Antje Prasse, Michael Kreuter et al. · The Lancet Respiratory Medicine · 2021 · 490 citations · Full text

Antifibrotic Therapy, Advanced Lung Disease, Idiopathic Pulmonary Fibrosis +6

Brain Natriuretic Peptide Is a Prognostic Parameter in Chronic Lung Disease

Hanno Leuchte, Rainer Baumgartner, Michal El Nounou et al. · American Journal of Respiratory and Critical Care Medicine · 2006 · 292 citations

Clinical significance of brain natriuretic peptide in primary pulmonary hypertension

Hanno Leuchte, Michael Holzapfel, Rainer Baumgartner et al. · Journal of the American College of Cardiology · 2004 · 288 citations

Hypertension, Pulmonary Arterial Hypertension, Pulmonary Circulation +9

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry

Jürgen Behr, Michael Kreuter, Marius M. Hoeper et al. · European Respiratory Journal · 2015 · 230 citations · Full text

Brain Natriuretic Peptide and Exercise Capacity in Lung Fibrosis and Pulmonary Hypertension

Hanno Leuchte, Claus Neurohr, Rainer Baumgartner et al. · American Journal of Respiratory and Critical Care Medicine · 2004 · 220 citations